acute myeloid leukemia

[International Immunology] To apply the iPSC-based cell therapy in an allogeneic setting, the authors developed a method in which non-T cell-derived iPSCs were transduced with exogenous T cell receptor genes.

[Molecular Medicine] TRIM14 promoted the proliferation of acute myeloid leukemia cells via activating PI3K/AKT pathway, which was reversed by human MSC-derived exosomes through delivering miR-23b-5p.

[Cell Death Discovery] Researchers performed high-throughput screening and identified that oridonin, an ent-kaurene diterpenoid extracted from the Chinese herb Rabdosia rubescens, inhibited DNMT3A R882 mutant leukemic cells at a low-micromolar concentration.

[Blood] Researchers showed that transcriptional downregulation of PU.1 was an active process involving an alternative promoter in intron 3 that was induced by RUNX transcription factors driving noncoding antisense transcription.

[LAVA Therapeutics N.V.] LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.

[Science Advances] Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.